A rational approach to PML for the clinician

ABSTRACT

The first step in the management of progressive multifocal leukoencephalopathy (PML) is awareness of the disease. Patients vulnerable to PML are those with immunosuppression, either through their disease or use of immune-modulating therapy. In patients susceptible to PML who exhibit focal neurologic signs and symptoms, brain magnetic resonance imaging can detect the telltale PML brain lesions—subcortical white matter hyperintense areas on T2-weighted images and fluid-attenuated inversion recovery sequences and hypointensity on T1-weighted images, typically without enhancement. Demonstration of JC virus DNA by ultrasensitive polymerase chain reaction in cerebrospinal fluid is diagnostic for PML. Immune restoration whenever possible is the cornerstone of treatment. Highly active antiretroviral therapy has dramatically improved the prognosis for patients infected with human immunodeficiency virus. Alternatively, restoration of immunity is frequently attended by the immune reconstitution inflammatory syndrome which can be clinically devastating or even fatal. In the case of natalizumab-associated PML, withdrawal of therapy and prompt institution of plasmapheresis to desaturate target receptors provides the best chance for long-term survival.

Our remarkable progress in understanding progressive multifocal leukoencephalopathy (PML) since its discovery more than 50 years ago has evolved in three stages, concurrent with the changing epidemiology of PML: the pre–human immunodeficiency virus (HIV) era; the HIV era, with highly active antiretroviral therapy (HAART) bringing further change; and the biologic therapy era. Before the appearance of HIV, PML developed mostly in patients who had lymphoma, other malignancies, and rare forms of immunosuppression. The development of HIV changed the nature of PML, with more than 75% of cases now reported in HIV-infected patients. Within the HIV population, the epidemiology and prognosis of PML have undergone additional changes since the late 1990s. The introduction of HAART transformed PML from an almost uniformly fatal and inexorably progressive disease to one in which long-term survival is expected, particularly in the setting of robust immune reconstitution.

The third and most recent stage in the evolution of PML and our understanding of it has coincided with the introduction and use of increasingly potent immunosuppressive regimens and novel biologic immunologic therapies that target various aspects of the integrated immune response. These agents are being applied not only in the field of autoimmune and autoinflammatory disease but also in transplantation and oncology. Collectively, vulnerable populations (ie, patients with lymphoreticular malignancies and autoinflammatory diseases) are now being subjected to therapies that singly or in combination have unknown effects on the immune system. As a byproduct, practitioners who were only vaguely aware of PML in the past now must consider PML in their differential diagnosis, develop a rational plan for evaluating such patients, and recognize when referral to a specialist is indicated. Recent descriptions of atypical forms of PML add to the challenge for clinicians, as do reports of cases of PML in patients with minimal immunosuppression, in the absence of immunosuppressive therapy, and in patients who appear to have “normal” immune systems but in fact have diseases such as sarcoidosis. Rare cases are also being reported in patients with advanced liver disease.

This article offers recommendations for enhanced awareness of PML, suggestions for improved evaluation of predisposed patients, and a summary of currently accepted treatment strategies.

WHEN TO SUSPECT PML

Consideration of PML in the differential diagnosis is based on the patient’s vulnerability and the signs and symptoms of the disease. In an otherwise immunologically healthy individual, PML rarely accounts for focal...
neurologic deficits. Clinicians should therefore focus their suspicions on individuals who are predisposed to PML (Table 1). Predisposed individuals are not always obvious; for example, HIV-positive individuals who have not been diagnosed with HIV infection may present with PML as the heralding manifestation of their disease.

Patients being treated with immunosuppressive biologic agents represent a significant group that is predisposed to PML. At one time, focal neurologic deficits were required to consider the possibility of PML, but cognitive/behavioral abnormalities rather than focal neurologic findings are often the presenting sign in individuals treated with immune-modulating biologic agents. This phenomenon is most strikingly observed in recipients of natalizumab. Any central nervous system (CNS) dysfunction in a patient taking an immunosuppressive biologic agent should arouse suspicion for PML.

Peripheral neuropathy is not caused by PML but can coexist with it. Accordingly, in patients with rheumatologic disease who are receiving immune modifiers, neuromuscular symptoms in the absence of brain abnormalities on magnetic resonance imaging (MRI) argue against consideration of PML but do not rule it out—especially in patients with connective tissue diseases.

Systemic lupus erythematosus (SLE) represents a special challenge for several reasons. First, SLE appears to be a predisposing factor among other connective tissue diseases. In addition, SLE is associated with a variety of CNS complications, including a spectrum of focal and diffuse signs and symptoms that can mimic PML and lead to underdiagnosis.

Underrecognition is a risk in the HIV population as well, where cognitive impairment is common. Irrespective of immune or virologic status, 57% of HIV patients demonstrate impairment on neuropsychiatric testing. Often, mild to moderate cognitive impairment in HIV is attributed to HIV encephalopathy with no further workup, resulting in a missed or late diagnosis of PML.

**IMAGING CONSIDERATIONS**

In the rheumatologic disease population, especially those with SLE, and the HIV population, neuroimaging is indicated in any patient who presents with cognitive impairment. Typical radiographic characteristics of PML on MRI are subcortical white matter hyperintense areas on T2-weighted images and fluid-attenuated inversion recovery. T1-weighted images will reveal hypointense lesions that usually do not enhance, but may do so in fewer than 10% of patients with PML. Typically, no mass effect is seen.

In addition to rare faint gadolinium enhancement of lesions, other lesion characteristics may depart from the classic picture—for example, white matter and gray matter involvement, and monofocal instead of multifocal lesions. In HIV-positive patients, MRI can demonstrate diffuse cerebellar atrophy and subtle white matter abnormalities within the cerebellum.

Unfortunately, nonspecific white matter lesions occur in HIV infection as well as connective tissue diseases, compromising diagnostic specificity of a single imaging study. Nevertheless, progression of clinical signs and symptoms and progressive MRI changes should prompt a more vigorous diagnostic evaluation for PML. Alternatively, a normal MRI in a patient in whom PML is suspected has strong negative predictive value. In either situation, baseline neuroimaging is not recommended.

**DIAGNOSIS AND REFERRAL**

A neurology consult is advised when a patient has a predisposing condition for PML or suspicious neurologic signs or symptoms, whether focal or diffuse, and in whom an MRI demonstrates white matter changes.

**Evaluation for JC virus DNA**

When the neurology consult has been scheduled, and before the actual visit to the neurologist, a cerebrospinal fluid (CSF) sample should be obtained and evaluated for JC virus (JCV) DNA using a highly sensitive polymerase chain reaction (PCR) assay. Lumbar puncture in the setting of possible PML is critical to exclude the presence of other opportunistic infections.

The importance of using ultrasensitive PCR assays for diagnosing PML cannot be overstated, as falsely negative CSF PCR has been observed for JCV DNA despite high levels of JCV DNA in spinal fluid when utilizing less sensitive assays. The most sensitive commercial assays can detect as few as 50 copies of JCV DNA per mL of CSF fluid.

The risk of PML imparted by biologic agents other than natalizumab and nonbiologic immunosuppressive agents has been difficult to quantify, but no immune-modifying drug or combination of drugs appears entirely

---

**TABLE 1**

**Situations that arouse suspicion of PML**

- Cognitive/behavioral abnormalities in patients receiving immune-modulating biologic agents, especially natalizumab
- Any central nervous system dysfunction in the presence of immunosuppressive biologic therapy
- Neurocognitive dysfunction in patients with systemic lupus erythematosus or human immunodeficiency virus infection
- In patients with predisposing conditions, the finding of white matter changes on magnetic resonance imaging in the presence of suspicious neurologic signs or symptoms

PML = progressive multifocal leukoencephalopathy
free of risk. Any patient who has had significant or pro-
longed immunosuppression should be considered vul-
nerable, and any patient with suspicion of PML based
on unexplained neurologic symptoms warrants CSF
examination for JCV DNA.

Brain biopsy
In patients with progressive clinical and MRI find-
ings that suggest PML, but whose CSF PCR for JCV DNA
is repeatedly negative, a brain biopsy is appropriate
regardless of background immunosuppression. In the
patient with rheumatologic disease, for example, suspi-
cion of PML should be heightened if there is neurologic
deterioration in the face of escalating antinflamma-
tory or immunosuppressive therapy for immune-driven
inflammatory disease. Diagnostic urgency is particu-
larly warranted in those disorders where the possibility
for immune reconstitution is highest (ie, those receiving
immunosuppressive regimens).

PML MANAGEMENT DEPENDS
ON CLINICAL SETTING

Management of PML starts with risk stratification to
identify those patients most prone to developing PML
based on their immune status; the presence of auto-
immune disease; the subtype of disease (in the case of
SLE); and the nature, intensity, and duration of their
immunosuppression. If a high-risk patient develops
signs and symptoms of PML, the diagnosis should be
anticipated and serious consideration given to with-
holding immunosuppressive therapies while the patient
is being worked up.

When PML is diagnosed, whether by demonstra-
tion of JCV in CSF or documented by brain biopsy in a
patient with a suggestive clinical picture, the appro-
priate management depends on the clinical setting (Table
2). In the HIV-infected patient who is not receiving
antiviral therapy, initiation of HAART is the core of
treatment. For natalizumab-treated patients, the stan-
dard approach is to discontinue natalizumab, institute
plasmapheresis to accelerate clearance of therapeutic
levels of natalizumab and increase the number and func-
tion of leukocytes entering the CNS, and monitor for
immune reconstitution.

Accelerating immune reconstitution
Once a diagnosis of PML is confirmed, immune recon-
stitution should be accelerated whenever possible. This
can include temporary or permanent withdrawal of
immunosuppressive therapy and initiation of plasmaph-
eresis. Evidence supports continuing plasma exchange
until natalizumab serum drug levels decline to less than
1 μg/mL to achieve desaturation of the alpha-4 integrin
receptor. Typically, desaturation of the targeted inte-
grin receptor occurs after five plasmapheresis sessions.

Immune reconstitution may also precipitate a syn-
drome known as the immune reconstitution inflam-
matory syndrome (IRIS), characterized by enlargement
and contrast enhancement of PML lesions, appear-
ance of new brain lesions, and worsening of neurologic
deficits. The infiltration of the brain with inflammatory
multinucleated cells and lymphocytes following abrupt
immune reconstitution requires treatment. Opinion
suggests that judicious use of corticosteroids may control
the immune response in the brain in patients with PML-
IRIS, although further studies are needed.

Involving the patient in treatment decisions
Because risk tolerance varies considerably among indi-
viduals, patients should be informed of the risks of PML
on the basis of their disease and the agents used to treat
it. They should also be given information about the
effects of individual treatments on the course of their
disease, and they should be encouraged to participate in
the selection of therapy.

SUMMARY

The approach to PML in the biologic era starts with
an increased awareness of the disease followed by rec-
ocognition of vulnerable populations and factors that
contribute to the development of PML, such as biologic
and nonbiologic immunosuppressive therapy. Optimal
management includes a low threshold for investigating
neurologic signs and symptoms and new-onset signs and
symptoms in vulnerable populations, the use of MRI to
detect typical PML brain lesions and other atypical brain
features (ie, cerebellar atrophy), lumbar puncture and
spinal CSF analysis to detect JCV DNA, and timely neu-
rologic consultation for further evaluation. Much still
needs to be learned about PML and the risks imparted by
background diseases and individual drugs used in rheu-
matologic, neurologic, and oncologic disease.

REFERENCES

multifocal leukoencephalopathy and other forms of JC virus disease.

| TABLE 2
<table>
<thead>
<tr>
<th>PML management summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV patients</td>
</tr>
<tr>
<td>Initiate highly active</td>
</tr>
<tr>
<td>antiretroviral therapy</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

HIV = human immunodeficiency virus; PML = progressive multifocal
leukoencephalopathy

Correspondence: Leonard Calabrese, DO, R.J. Fasenmyer Chair of Clinical Immunology, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, 9500 Euclid Ave., A50, Cleveland, OH 44195; calabrl@ccf.org